Quick, high-volume test offers fast track in search for Alzheimer's drugs

Nov 15, 2012
The D737 compound was tested on flies with a regular human A gene (top graph) and flies with a mutant gene that causes extra buildup of the peptide (bottom graph). For each group, flies received none of the compound (black line), or concentrations of 2, 20 or 200 micromolar (blue, grey and red lines, respectively). Flies -- particularly those with the mutant gene -- survived longer when administered the compound. Credit: Angela Fortner McKoy

(Phys.org)—An efficient, high-volume technique for testing potential drug treatments for Alzheimer's disease uncovered an organic compound that restored motor function and longevity to fruit flies with the disease, according to new research that could help put the search for an effective Alzheimer's drug on a faster track.

Princeton University researchers report in the that they discovered an organic compound that prevented the formation of protein , or aggregates, found on human brain cells afflicted by Alzheimer's disease. The researchers realized the compound's potential via a high-throughput—meaning many materials can be examined at once—screening process developed at Princeton that examined the ability of 65,000 to inhibit protein aggregation.

When administered to fruit flies bred to exhibit Alzheimer's-like symptoms, the compound—which the researchers call D737—restored climbing ability and increased the flies' lifespan by several days in comparison to flies that did not receive the compound, the researchers reported.

The compound worked by stopping the accumulation of a peptide known as amyloid beta 42 (Aβ42), which disrupts cell function, is found in high quantities in Alzheimer's plaques, and is thought to initiate the disease's characteristic neural deterioration. The fruit flies were genetically engineered at the University of Cambridge to have human Aβ42 collect in their neurons. As in humans, this accumulation results in memory and mobility loss, and early death.

Senior researcher Michael Hecht, a Princeton professor of chemistry, said the findings demonstrate a quick and efficient screening method that could help in the search for a medicinal defense against Alzheimer's. Currently, he said, the disease's proliferation in an has outpaced the success of efforts todevelop a treatment for it.

"As the population ages, Alzheimer's is the big disease," Hecht said. "There are drugs to control symptoms, but nothing to treat the disease itself. One approach could be to control peptide aggregation as we have done, but the compounds tested so far often fail.

This video is not supported by your browser at this time.
Princeton University researchers used a high-throughput -- meaning many materials can be examined at once -- screening process developed at Princeton to discover an organic compound that prevented the formation of protein clumps found on human brain cells afflicted by Alzheimer's disease. Fruit flies bred to exhibit Alzheimer's-like symptoms maintained their climbing ability after receiving the compound -- called D737 -- for two weeks (left), whereas flies that did not (right) get treatment exhibited the disorientation and loss of mobility associated with Alzheimer's. Credit: Angela Fortner McKoy

"Our technique would allow scientists to create an artificial genetic system, examine it with a high-throughput screen and find whether it works," Hecht said. "From that they can fish out the best results and test them in other models."

Furthermore, an effective compound such as D737 can reveal information about Aβ42's structure that can be used to formulate other treatments, said lead author Angela Fortner McKoy, a postdoctoral researcher at Rutgers University who received her Ph.D. in chemistry from Princeton in 2011. Fortner McKoy and Hecht worked with second author Jermont Chen, who earned his Ph.D. in chemistry from Princeton in 2008, andTrudi Schüpbach, the Henry Fairfield Osborn Professor of Biology.

The Princeton researchers used a screening process developed in the Hecht lab to specifically identify Aβ42 aggregation. First reported in the journal ACS Chemical Biology in 2006, the technique hinges on a fusion of Aβ42 and green fluorescent protein—which glows under ultraviolet light and is found in animals such as jellyfish—that is expressed in the bacteria E. coli. The fluorescent protein does not glow when Aβ42 is able to aggregate. When a compound such as D737 inhibits peptide clumping, however, the E. coli bacterium appears bright green. The efficiency of the screening system stems from the relative simplicity of attaining andworking with E. coli, a standard laboratory bacterium, Hecht said.

For the current research, Hecht and his co-authors examined 65,000 randomly chosen that Chen acquired from the Broad Institute of the Massachusetts Institute of Technology and Harvard University. The technique revealed 269 compounds that halted the buildup of Aβ42 aggregates. Of those, Fortner McKoy selected the eight most readily available for further testing. Fortner McKoy found that D737 best prevented the accumulation of Aβ42 and reduced mortality in cell cultures. In addition, the researchers found that the compound reduced the production and accumulation of reactive oxygen species, which damage cells.

Flies bred to express the Alzheimer's peptide A maintained their climbing ability longer after receiving the D737 compound (black bars) than flies that did not receive the compound (gray bars). The top panel shows flies with the standard A gene, while the bottom panel shows flies with a disease-causing mutant gene. Credit: Angela Fortner McKoy

The researchers then tested the compound on healthy fruit flies with no Aβ42 accumulation, as well as on flies with a regular human-form Aβ42 gene and flies with a mutant gene—which is found in some humans with Alzheimer's—that causes extra buildup of the peptide. For each of these three fly types, one group of flies did not receive D737 while another group was given the compound in concentrations of 2, 20 or 200 micromolar.

In the flies with regular and accelerated Aβ42 buildup, those receiving D737 lived an average of four to six days longer than similarly altered flies that were not fed the compound. The healthy fruit flies that received D737 showed no change in , demonstrating that the compound is non-toxic in fruit flies, Hecht said.

To test mobility, the researchers put 20 flies from both of the genetically altered groups into the bottom of a vial and recorded how many had climbed to the top. After 38 days, only 6 percent of untreated flies with normal Aβ42 accumulation could climb, as opposed to as many as 34 percent of the flies receiving D737.

In flies with the mutant Aβ42 gene, all those left untreated lost mobility after 27 days. Of those given the compound, however, 50 to 78 percent—depending on the dosage—could still climb after the same time period.

Damian Crowther, a group leader in the Department of Genetics at Cambridge who created and supplied the flies used in the Princeton research but had no active role in the work, said that D737 demonstrated a notable ability to suppress in the same neurological, physical and mental deficits seen in humans with Alzheimer's.

"It's not common to see such a strong effect in the fly model. Of the compounds that my lab tests, which have been through rigorous in vitro screening, we see effects as good as this in only 5 to 10 percent," Crowther said. "To find that a compound administered orally is able to show beneficial effects on both of these fly phenotypes indicates that the drug can access the neurons and, once within the brain, presumably control the aggregation of amyloid beta ."

Crowther said the Princeton research further supports the approach of curbing the buildup of Aβ42 and related variants of the amyloid beta peptide to treat Alzheimer's. In the middle stages of accumulation, variations of the peptide can be highly toxic to and kill them, he said. But the work by Hecht and his co-authors helps show that blocking amyloid-beta aggregation can be safe and potent.

"There is always a worry when looking for aggregation-blocking agents that the aggregation process may be interrupted at the wrong point," Crowther said.

"Further work should try to characterize in an in vivo system exactly where this compound halts or modifies the aggregation process," he said. "For a beneficial effect we don't need to completely block aggregation—indeed, amyloid formation is a thermodynamically inevitable process. It could be that the compound simply modulates the aggregation process so that the most toxic intermediates are less populated."

Although the compound's success in flies would not necessarily translate to humans, Fortner McKoy said, its effectiveness illustrates that worthwhile treatment candidates can be uncovered with the Princeton .

"It inhibited the peptide aggregation effectively enough so that we could see an improvement in the flies," Fortner McKoy said. "In general, a compound like this would be further developed and changes would be made to it to test its efficacy in humans. But the fly results show that it is worth testing this compound in another model."

Explore further: Breakthrough points to new drugs from nature

More information: The paper, "A novel inhibitor of Aβ peptide aggregation: From high throughput screening to efficacy in an animal model for Alzheimer's disease," was published Nov. 9 in the Journal of Biological Chemistry. www.jbc.org/content/287/46/38992.abstract

Related Stories

The good and the bad of a potential Alzheimer's target

Jun 27, 2008

Research in fruit flies has shown that enhancing the production of a protein called neprilysin can reduce the formation of plaques and neuron death associated with Alzheimer's, at the expense of reducing the flies' lifespan.

Turmeric-based drug effective on Alzheimer flies

Feb 14, 2012

Curcumin, a substance extracted from turmeric, prolongs life and enhances activity of fruit flies with a nervous disorder similar to Alzheimers. The study conducted at Linköping University, indicates ...

Eye of a fruit fly

Oct 05, 2011

(Medical Xpress) -- A tiny fruit fly's retina may hold the key to understanding the cause of the progression of Alzheimer's disease, according to a newly published study by researchers at the University of ...

Active compounds against Alzheimer's disease

Jan 12, 2012

More than half of all cases of dementia in the elderly can be attributed to Alzheimer's disease. Despite vast research efforts, an effective therapy has not been developed, and treatment consists of dealing with the symptoms. ...

Recommended for you

Breakthrough points to new drugs from nature

Apr 16, 2014

Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds which could form the basis of novel therapeutic drugs.

World's first successful visualisation of key coenzyme

Apr 16, 2014

Japanese researchers have successfully developed the world's first imaging method for visualising the behaviour of nicotine-adenine dinucleotide derivative (NAD(P)H), a key coenzyme, inside cells. This feat ...

User comments : 0

More news stories

A greener source of polyester—cork trees

On the scale of earth-friendly materials, you'd be hard pressed to find two that are farther apart than polyester (not at all) and cork (very). In an unexpected twist, however, scientists are figuring out ...

Cosmologists weigh cosmic filaments and voids

(Phys.org) —Cosmologists have established that much of the stuff of the universe is made of dark matter, a mysterious, invisible substance that can't be directly detected but which exerts a gravitational ...